Evidence map›Paper›PMID 34784388›Full record

ArticlePLoS pathogens2021

Knockout of Anopheles stephensi immune gene LRIM1 by CRISPR-Cas9 reveals its unexpected role in reproduction and vector competence.

Ehud Inbar, Abraham G Eappen, Robert T Alford, William Reid, Robert A Harrell, Maryam Hosseini, Sumana Chakravarty, Tao Li, B Kim Lee Sim, Peter F Billingsley and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Applications of CRISPR in Parasitology.Current pharmaceutical biotechnology · 2025
    Review
  6. Article
  7. Article
  8. Novel systems to study vector-pathogen interactions in malaria.Frontiers in cellular and infection microbiology · 2023
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ehud InbarSanaria Inc. Rockville, Maryland, United States of America.
Abraham G EappenSanaria Inc. Rockville, Maryland, United States of America.
Robert T AlfordInsect Transformation Facility, Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, United States of America.
William ReidSanaria Inc. Rockville, Maryland, United States of America.ORCID 0000-0002-8130-6516
Robert A HarrellInsect Transformation Facility, Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, United States of America.ORCID 0000-0002-6970-1396
Maryam HosseiniSanaria Inc. Rockville, Maryland, United States of America.
Sumana ChakravartySanaria Inc. Rockville, Maryland, United States of America.
Tao LiSanaria Inc. Rockville, Maryland, United States of America.
B Kim Lee SimSanaria Inc. Rockville, Maryland, United States of America.
Peter F BillingsleySanaria Inc. Rockville, Maryland, United States of America.
Stephen L HoffmanSanaria Inc. Rockville, Maryland, United States of America.ORCID 0000-0002-0700-9505
Sanaria · USInstitute for Bioscience and Biotechnology Research

Funding

Transgenic Mosquitoes for Improved Malaria Sporozoite Vaccine ManufactureR44AI077262 · NIAID · SANARIA, INC. · PI BILLINGSLEY, PETER F. · 2012 to 2014
$3.0M
Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine ManufactureR44AI131806 · NIAID · SANARIA, INC. · PI BILLINGSLEY, PETER F. · 2017 to 2019
$2.9M
Improving Production of Attenuated Malaria Sporozoite Vaccines through Genetic MoR43AI077262 · NIAID · SANARIA, INC. · PI BILLINGSLEY, PETER F. · 2008 to 2009
$600k
NIAID NIH HHS R43 AI077262NIAID NIH HHS R44 AI077262NIAID NIH HHS R44 AI131806
6 · The paper itself

Abstract

PfSPZ Vaccine against malaria is composed of Plasmodium falciparum (Pf) sporozoites (SPZ) manufactured using aseptically reared Anopheles stephensi mosquitoes. Immune response genes of Anopheles mosquitoes such as Leucin-Rich protein (LRIM1), inhibit Plasmodium SPZ development (sporogony) in mosquitoes by supporting melanization and phagocytosis of ookinetes. With the aim of increasing PfSPZ infection intensities, we generated an A. stephensi LRIM1 knockout line, Δaslrim1, by embryonic genome editing using CRISPR-Cas9. Δaslrim1 mosquitoes had a significantly increased midgut bacterial load and an altered microbiome composition, including elimination of commensal acetic acid bacteria. The alterations in the microbiome caused increased mosquito mortality and unexpectedly, significantly reduced sporogony. The survival rate of Δaslrim1 mosquitoes and their ability to support PfSPZ development, were partially restored by antibiotic treatment of the mosquitoes, and fully restored to baseline when Δaslrim1 mosquitoes were produced aseptically. Deletion of LRIM1 also affected reproductive capacity: oviposition, fecundity and male fertility were significantly compromised. Attenuation in fecundity was not associated with the altered microbiome. This work demonstrates that LRIM1's regulation of the microbiome has a major impact on vector competence and longevity of A. stephensi. Additionally, LRIM1 deletion identified an unexpected role for this gene in fecundity and reduction of sperm transfer by males.

Indexed as

CRISPR-Cas SystemsReproductionAnimalsAnophelesBacteriaDigestive SystemFemaleInsect ProteinsMalariaMaleMosquito VectorsPlasmodiumInsect Proteins

Identifiers

PMID34784388
PMCPMC8631644
OpenAlexW3214131510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.